Clinical Trials - April 13, 2026
Diamyd Medical discontinues Phase 3 trial and initiates strategic review
Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.
Clinical Trials - April 1, 2026
Cereno Scientific reports 12-month data
The company has announced initial learnings from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH).
Clinical Trials - March 31, 2026
Affibody reports positive Phase 3 data
The company has announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS).
Clinical Trials - March 25, 2026
Verigraft initiates Phase II/III trial of its personalized tissue engineered vein
The company has announced the initiation of a pivotal Phase II/III trial of its P-TEV (personalized tissue engineered vein) in patients with chronic venous insufficiency (CVI), supported by USD 10 million from existing investors.
Clinical Trials - March 23, 2026
BioArctic presents new data on long-term, real-world treatment with lecanemab
BioArctic’s partner Eisai presented the data at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders, held in Copenhagen, Denmark March 17-21.
Clinical Trials - March 20, 2026
Lundbeck advances Parkinson’s research with new Phase 1b data
The company has presented new data from a Phase 1b proof-of-mechanism trial of Lu AF28996, a novel compound invented by Lundbeck with dopamine D1/D2 receptor agonist activity.
